L

ast June, Vermont became the first state in the country to pass a law requiring drug makers to justify their price hikes. The move, which was opposed by the pharmaceutical industry, was borne out of frustration that the federal government had not acted on the rising cost of prescription medicines. But the law has its limits, as indicated by the first report by the state attorney general, which was issued last month. Confidential data will not be publicly released and the state has no power to do anything about prices, other than issue $10,000 fines to companies that fail to comply. We spoke with Chris Pearson, a Vermont legislator who was vice chair of the House Committee on Health Care and championed the bill, about the results and where this is headed. This is an edited version of our conversation …

Pharmalot: What was the hope when you pushed for this law?

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.